CLINICAL TRIAL SUMMARY

MDACC Study No:2014-0145 (clinicaltrials.gov NCT No: NCT02124746)
Title:Open-label Study to Assess the Long-term Safety and Efficacy
of Momelotinib in Subjects with Primary Myelofibrosis,
Post-polycythemia Vera Myelofibrosis, Post-essential
Thrombocythemia Myelofibrosis, Polycythemia Vera or
Essential Thrombocythemia
Principal Investigator:Srdan Verstovsek
Treatment Agent:Momelotinib
Study Status:Open
Study Description:The goal of this clinical research study is to learn about the long-term safety
of giving momelotinib (MMB) to patients with primary myelofibrosis,
post-polycythemia vera myelofibrosis, post-essential thrombocythemia
myelofibrosis, polycythemia vera, or essential thrombocythemia. Researchers
also want to learn if MMB can help to control the disease.

Hide details for General InformationGeneral Information

Disease Group:Leukemia; Myeloproliferative Diseases
Phase of Study:Phase II/Phase III
Treatment Agents:Momelotinib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Gilead Sciences
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Srdan Verstovsek
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults